Results 81 to 90 of about 164,819 (283)
Objective The Phase 3 MANDARA study demonstrated non‐inferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair +14 more
wiley +1 more source
ABSTRACT Ryanodine receptor type 2 (RYR2) is a large calcium channel that has been identified as one of the most frequently mutated genes in lung adenocarcinoma (LUAD). Despite its potential significance, the role of RYR2 in LUAD remains poorly understood.
Tao Wang +3 more
wiley +1 more source
Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels
This review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Guilherme Suarez‐Kurtz
wiley +1 more source
Myopathies encompass a wide variety of acquired and hereditary disorders. The pathomechanisms include structural and functional changes affecting, e.g., myofiber metabolism and contractile properties. In this study, we observed increased passive tension (
A. Unger +9 more
semanticscholar +1 more source
Absolute bioavailability and intravenous pharmacokinetics of N‐acetyl‐D‐mannosamine in humans
Aims N‐acetyl‐D‐mannosamine monohydrate (ManNAc) is a naturally occurring monosaccharide that has attracted considerable attention for its potential in treating GNE myopathy, a rare autosomal recessive muscle disorder. Despite its promise as an oral treatment, the absolute bioavailability of oral ManNAc has not been determined and there has been no ...
Tahlia R. Meola +6 more
wiley +1 more source
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch +9 more
wiley +1 more source
Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami +2 more
wiley +1 more source
Patients with chronic heart failure and predominant left atrial versus left ventricular myopathy
Background Left atrial (LA) and ventricular (LV) functional impairment often co-exist in patients with heart failure (HF). However, some patients with HF have a disproportionate LA or LV dysfunction.
Xuanyi Jin +11 more
doaj +1 more source
Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy
The genetic basis of oculopharyngeal muscular dystrophy (OPMD) is a short expansion of a polyalanine tract (normal allele: 10 alanines, mutant allele: 11–17 alanines) in the nuclear polyadenylate binding protein PABPN1 which is essential for controlling ...
Ami Mankodi +5 more
doaj +1 more source
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel +13 more
wiley +1 more source

